JP2011522874A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522874A5
JP2011522874A5 JP2011513069A JP2011513069A JP2011522874A5 JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5 JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5
Authority
JP
Japan
Prior art keywords
influenza
virus
virus strain
vaccine
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011513069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522874A (ja
Filing date
Publication date
Priority claimed from GBGB0905570.8A external-priority patent/GB0905570D0/en
Application filed filed Critical
Publication of JP2011522874A publication Critical patent/JP2011522874A/ja
Publication of JP2011522874A5 publication Critical patent/JP2011522874A5/ja
Pending legal-status Critical Current

Links

JP2011513069A 2008-06-12 2009-06-12 季節性および汎流行性の防御のための混合インフルエンザワクチン Pending JP2011522874A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13191808P 2008-06-12 2008-06-12
US61/131,918 2008-06-12
GBGB0905570.8A GB0905570D0 (en) 2009-03-31 2009-03-31 Combined vaccines
GB0905570.8 2009-03-31
PCT/IB2009/006038 WO2009150532A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection

Publications (2)

Publication Number Publication Date
JP2011522874A JP2011522874A (ja) 2011-08-04
JP2011522874A5 true JP2011522874A5 (enExample) 2012-07-19

Family

ID=40672059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011513069A Pending JP2011522874A (ja) 2008-06-12 2009-06-12 季節性および汎流行性の防御のための混合インフルエンザワクチン

Country Status (9)

Country Link
US (2) US20110200635A1 (enExample)
EP (1) EP2303321A1 (enExample)
JP (1) JP2011522874A (enExample)
KR (1) KR20110019417A (enExample)
CN (1) CN102245203A (enExample)
AU (1) AU2009259006A1 (enExample)
CA (1) CA2727322A1 (enExample)
GB (1) GB0905570D0 (enExample)
WO (1) WO2009150532A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9764024B2 (en) * 2008-11-28 2017-09-19 Statens Serum Institut Optimized influenza vaccines
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
EP2424565A1 (en) * 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
WO2011044152A1 (en) * 2009-10-05 2011-04-14 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Protection against pandemic and seasonal strains of influenza
JP2013520172A (ja) 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
JP5884100B2 (ja) * 2011-08-31 2016-03-15 公益財団法人東京都医学総合研究所 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するDIs株由来組換えワクシニアウイルス
EP4241785A3 (en) 2011-09-20 2023-09-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2866465A1 (en) * 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
HK1215546A1 (zh) 2012-12-17 2016-09-02 Eurocine Vaccines Ab 鼻内接种疫苗给药方案
WO2014099931A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3060247A1 (en) * 2013-10-25 2016-08-31 Leukocare Ag A novel method for the production of stabile vaccines
WO2016100926A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
JP6719388B2 (ja) * 2014-12-25 2020-07-08 テルモ株式会社 皮内投与インフルエンザワクチン組成物
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3743107A1 (en) * 2018-01-22 2020-12-02 The United States of America, as represented by the Secretary, Department of Health and Human Services Broadly protective inactivated influenza virus vaccine
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
KR20070116651A (ko) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 조성물
EP2377552A3 (en) * 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
AU2006310341B2 (en) * 2005-11-04 2011-01-06 Novartis Vaccines And Diagnostics Limited Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
WO2007144772A2 (en) * 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
KR20090057015A (ko) * 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
EA200900784A1 (ru) * 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
WO2008091657A1 (en) * 2007-01-23 2008-07-31 Academia Sinica Flu vaccines and methods of use thereof
GB0810305D0 (en) * 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
AU2009227674C1 (en) * 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens

Similar Documents

Publication Publication Date Title
JP2011522874A5 (enExample)
Becker et al. Influenza vaccines: successes and continuing challenges
Vasou et al. Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses
Kumar et al. Novel platforms for the development of a universal influenza vaccine
Cappellano et al. Nano-microparticle platforms in developing next-generation vaccines
Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the elderly population
Cargnin Faccin et al. Pandemic preparedness through vaccine development for avian influenza viruses
Sekiya et al. Selecting and using the appropriate influenza vaccine for each individual
Zhang et al. Universal influenza vaccines, a dream to be realized soon
JP6185548B2 (ja) インフルエンザワクチンの製造方法
Sebastian et al. Clinical advances in viral-vectored influenza vaccines
Vemula et al. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness
Li et al. Adjuvantation of influenza vaccines to induce cross-protective immunity
Clegg et al. Clinical vaccine development for H5N1 influenza
Budimir et al. Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration
ES2469568T3 (es) Vacuna contra la gripe
Quan et al. Progress in the development of virus-like particle vaccines against respiratory viruses
Trucchi et al. Universal influenza virus vaccines: what needs to happen next?
Hatz et al. A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects
El Sahly et al. Pandemic H5N1 influenza vaccine development: an update
Deans et al. Influenza vaccines provide diminished protection but are cost‐saving in older adults
Esposito et al. Preventing influenza in younger children
CN105342982B (zh) 经鼻给药的流感疫苗免疫制剂及其制备方法
Chu et al. Respiratory viruses and virus-like particle vaccine development: how far have we advanced?
EP2822585B1 (en) Improved vaccination against influenza